Limited coverage drugs – cyproterone
Last updated on October 7, 2022
| Generic name | Strength | Form |
|---|---|---|
|
cyproterone |
100 mg/1 mL | ampoule |
|
cyproterone |
50 mg | tablet |
|
Special Authority criteria |
Approval period |
|---|---|
|
Indication of need to reduce aggressive sexual drive |
Indefinite |
Practitioner exemptions
- None
Special notes
- Criteria applicable for all plans including Plan G
- For any cancer related condition, please contact the British Columbia Cancer Agency at 604-877-6098 Ext. 4610